Targeting Advanced Lung Cancer with Osimertinib Alone or with Bevacizumab

Recruiting · Phase 3 · Advanced Lung Non-Squamous Non-Small Cell Carcinoma and related conditions · 44 states

Check if I qualify View on ClinicalTrials.gov

About this trial

This trial looks at how well osimertinib works alone compared to when it is combined with bevacizumab for patients with advanced lung cancer that has a mutation in a gene called EGFR. The goal is to see if the combination helps control the cancer longer and improves outcomes. Osimertinib is a medicine that helps stop cancer cell growth, while bevacizumab works by cutting off the blood supply to tumors. Together, they may help patients live longer.

The trial's ID number is NCT04181060. This is a Phase 3 trial, which means it is testing how well the treatments work and how safe they are. It is regulated by the FDA and aims to include about 300 participants.

Who can join

This study is for adults aged 18 and older with non-squamous non-small cell lung cancer that has spread and has an EGFR mutation. People who have had certain previous treatments or have specific health risks may not be eligible. The trial team will confirm who can join.

Conditions

Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Participants are randomly placed in one of two groups. In Arm A, patients take osimertinib by mouth every day. In Arm B, patients also take osimertinib and receive bevacizumab through an IV on the first day of each treatment cycle. Both groups will have regular tests and check-ups during the trial.